Corrections: Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study (The Lancet Respiratory Medicine (2017) 5(6) (500–511) (S2213260017301741) (10.1016/S2213-2600(17)30174-1));Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study

The Lancet Respiratory Medicine

Volumn 5, Issue 6, 2017, Pages 500-511

  Beigel, John H ^a   Tebas, Pablo ^b,s   Elie Turenne, Marie Carmelle ^c,s   Bajwa, Ednan ^d,s   Bell, Todd E ^e,s   Cairns, Charles B ^f,s   Shoham, Shmuel ^g,s   Deville, Jaime G ^i,s   Feucht, Eric ^j,s   Feinberg, Judith ^k,s   Luke, Thomas ^l   Raviprakash, Kanakatte ^m   Danko, Janine ^o,s   O'Neil, Dorothy ^p   Metcalf, Julia A ^q   King, Karen ^h   Burgess, Timothy H ⁿ   Aga, Evgenia ^r   Lane, H Clifford ^q   Hughes, Michael D ^r   Davey, Richard T ^q   Quinn, Joseph ^s   Jiang, Yan ^s   Hoelle, Robyn ^s   Iovine, Nicole ^s   Wills, Robert Shawn ^s   Pata, Socorro ^s   Huggins, Monique ^s   Manukian, Belinda ^s   Holland, Carrie ^s   Brait, Kelsey ^s   Hunt, Taylor ^s   Stowell, Christopher ^s   Slater, Amy ^s   Townsends, Mary ^s   Quackenbush, Eugenia B ^s   Park, Yara A ^s   Jordan, Paul Gaither ^s   Blanchet, Cherie ^s   Chronowski, Kevin ^s   Alvarez, Kathleen ^s   Ostrander, Darin ^s   Woessner, Terry ^s   Thoman, Sandra ^s   Lin, James ^s   Ziman, Alyssa ^s   Shankar, Kavita ^s   Blok, Tom ^s   Batts, Don ^s   Beck, Bob ^s   Massey, Gail ^s   Bradley, Carol ^s   Carey, Patricia ^s   Baer, Jenifer ^s   Whitehead, Eva Moore ^s   Kohrs, Sharon ^s   Giulitto, Robert ^s   Schofield, Christina ^s   Fairchok, Mary ^s   Chambers, Susan ^s   Baker, Cindy ^s   RN, ^s   Parker, Michelle ^s   Harshbarger, Marta ^s   Nguyen, M Hong ^s   Carey, Mary Ellen ^s   Paronish, Julie ^s   Cornell, Frank ^s   Cramer, Jim ^s   Pakstis, Diana Lynn ^s   Ison, Michael G ^s   Wunderink, Richard ^s   Glesby, Marshall ^s   Ham, Kirsis ^s   Hughes, Valery ^s   Cushing, Melissa ^s   Goss, Cheryl ^s   Grenade, Joanne ^s   Park, Pauline K ^s   Napolitano, Lena M ^s   Raghavendran, Krishnan ^s   Hyzy, Robert C ^s   Davenport, Robertson ^s   Brierley, Kristin ^s   Downs, Theresa ^s   Gong, Michelle Ng ^s   Uehlinger, Joan ^s   Lin, Michael ^s   Fritsche, Janice ^s   Green, Tondria ^s   McLeod, Bruce ^s   Patel, Deena ^s   Bavaro, Mary F ^s   Deiss, Robert ^s   Brandt, Carolyn ^s   Cammarata, Stephanie ^s   Kremp, Allan ^s   Hollis Perry, Karine ^s   Lalani, Tahaniyat ^s   Banks, Susan ^s   Johnson, Jacqueline ^s   Maguire, Jason ^s   McNiff, Janet ^s   Rigg, Leslie E ^s   Ganesan, Anuradha ^s   Barahona, Irma ^s   Spencer, Steven ^s   Stagliano, David ^s   Burgess, Timothy ^s   Talmor, Daniel ^s   Mohammed, Monique ^s   Banner Goodspeed, Valerie ^s   Salata, Robert ^s   Finberg, Robert ^s   Wang, Jennifer ^s   Longtine, Karen ^s   Longtine, Jaclyn ^s   O'Neil, Mellissa ^s   Bauer, Philippe R ^s   Gajic, Ognjen ^s   Weist, Suanne M ^s   Sevransky, Jonathan ^s   Brown, Mona ^s   Roback, John ^s   Oropello, John ^s   Twohig, Bridget ^s   Jhang, Jeffrey ^s   Seethala, Rahgu ^s   Chen, Wilbur H ^s   Fontaine, Magali ^s   Saharia, Kapil ^s   Husson, Jennifer ^s   DeBiasi, Roberta ^s   Wilson, Jurran L ^s   Criss, Valli Ree ^s   Voell, Jocelyn ^s   Leitman, Susan ^s   Atkins, James Wade ^s   Patel, Hemaxi ^s   Paige, Traci ^s   Cantilena, Cathy ^s   more..

^a FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^k UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^l Henry Jackson Foundation for the Advancement of Military Medicine   (United States)

^m NAVAL MEDICAL RESEARCH CENTER   (United States)

ⁿ UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^o WALTER REED ARMY MEDICAL CENTER   (United States)

^p SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^q NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^r HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^s NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; OXYGEN;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ANTIBODY TITER; APACHE; ARTICLE; ARTIFICIAL VENTILATION; BREATHING RATE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HAZARD RATIO; HEMAGGLUTINATION INHIBITION; HUMAN; HYPOXIA; INFLUENZA; INFLUENZA A; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA B; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; OXYGEN SATURATION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PREGNANT WOMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; TACHYPNEA; VIRUS SHEDDING; AGED; BLOOD COMPONENT THERAPY; CASE CONTROL STUDY; CLINICAL TRIAL; KAPLAN MEIER METHOD; LENGTH OF STAY; MIDDLE AGED; PLASMA; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ADULT; AGED; BLOOD COMPONENT TRANSFUSION; CASE-CONTROL STUDIES; FEMALE; HUMANS; INFLUENZA, HUMAN; KAPLAN-MEIER ESTIMATE; LENGTH OF STAY; MALE; MIDDLE AGED; PLASMA; RESPIRATION, ARTIFICIAL; TREATMENT OUTCOME;

EID: 85019564290     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(17)30225-4     Document Type: Erratum

References (15)

1. Luke, TC, Kilbane, EM, Jackson, JL, Hoffman, SL, Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?. Ann Intern Med 145 (2006), 599–609.
2. Hung, IF, To, KK, lee, CK, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 52 (2011), 447–456.
3. The ANZIC Influenza Investigators. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med 361 (2009), 1925–1934.
4. Davies, A, Jones, D, Bailey, M, et al., Australia and New Zeland Extracorporeal Membrane Oxygenation Influenza Investigators. Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) acute respiratory distress syndrome. JAMA 302 (2009), 1888–1895.
5. Dominguez-Cherit, G, Lapinsky, SE, Macias, AE, et al. Critically ill patients with 2009 influenza A(H1N1) in Mexico. JAMA 302 (2009), 1880–1887.
6. Kumar, A, Zarychanski, R, Pinto, R, et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 302 (2009), 1872–1879.
7. Knaus, WA, Draper, EA, Wagner, DP, et al. APACHE II: a severity of disease classification system. Crit Care Med 13 (1985), 818–829.
8. Pollack, MM, Patel, KM, Ruttimann, UE, PRISM III: an updated pediatric risk of mortality score. Crit Care Med 24 (1996), 743–752.
9. England, PH, MERS-CoV: clinical decision making support for treatment. https://www.gov.uk/government/publications/mers-cov-clinical-decision-making-support-for-treatment (accessed Nov 8, 2016).
10. Mair-Jenkins, J, Saavedra-Campos, M, Baillie, JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 211 (2015), 80–90.
11. Hung, IF, To, KK, Lee, CK, et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest 144 (2013), 464–473.
12. Ison, MG, de Jong, MD, Gilligan, KJ, et al. End points for testing influenza antiviral treatments for patients at high risk of severe and life-threatening disease. J Infect Dis 201 (2010), 1654–1662.
13. Cheung, DH, Tsang, TK, Fang, VJ, et al. Association of oseltamivir treatment with virus shedding, illness, and household transmission of influenza viruses. J Infect Dis 212 (2015), 391–396.
14. US Food and Drug Administration. Guidance for industry influenza: developing drugs for treatment and/or prophylaxis, 2011, US Food and Drug Administration, Silver Spring, MD.
15. Ohmit, SE, Petrie, JG, Cross, RT, Johnson, E, Monto, AS, Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis 204 (2011), 1879–1885.